Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of liraglutide and dapagliflozin on cardiovascular and brain outcomes in type 2 diabetes
ChiCTR2100045401Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide and dapagliflozin in type 2 diabetes mellitus (T2DM), atherosclerotic disease, chronic kidney disease (CKD) and 2 more (3 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: major adverse cardiovascular events. Started Apr 2021; status: recruiting.
02
Drugs
liraglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic diseasechronic kidney disease (CKD)brain infarctionmyocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100045401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045401.